Jason Lee joined Centerview Partners in 2012 and is a Partner in the firm’s San Francisco office. At Centerview, Mr. Lee has advised a broad range of life sciences companies on strategic advisory assignments involving transactions with an aggregate value exceeding $220 billion.

Mr. Lee’s healthcare transactions include advising Seagen on its sale to Pfizer for $44 billion; Immunomedics on its sale to Gilead for $21 billion; Array BioPharma on its sale to Pfizer for $11.8 billion; Blueprint Medicines on its sale to Sanofi for up to $9.5 billion; Mirati on its sale to Bristol Myers Squibb for up to $5.8 billion; Gilead on its acquisition of Tubulis GmbH for up to $5.0 billion; Alpine Immune Sciences on its sale to Vertex Pharmaceuticals for $4.9 billion; Forty Seven Therapeutics on its sale to Gilead for $4.9 billion; Dicerna Pharmaceuticals on its sale to Novo Nordisk for $3.3 billion; MorphoSys on its sale to Novartis for €2.8 billion; ArQule on its sale to Merck for $2.7 billion; Day One Biopharmaceuticals on its sale to Servier for $2.5 billion; Ra Pharma on its sale to UCB for $2.5 billion; Synthorx on its sale to Sanofi for $2.5 billion; Dice Therapeutics on its sale to Eli Lilly for $2.4 billion; Gilead on its acquisition of Ouro Medicines for up to $2.2 billion and its strategic collaboration with Galapagos NV; Capstan Therapeutics on its sale to AbbVie for up to $2.1 billion; Poseida Therapeutics on its sale to Roche for up to $1.5 billion; Imago Biosciences on its sale to Merck for $1.3 billion; and Lengo Therapeutics on its sale to Blueprint for up to $465 million.

Other notable transactions include advising Pharmacyclics on its sale to AbbVie for $21 billion; Kite Pharma on its sale to Gilead for $11.9 billion; Onyx on its sale to Amgen for $10.4 billion; InterMune on its sale to Roche for $8.9 billion; AveXis on its sale to Novartis for $8.7 billion; GW Pharmaceuticals on its sale to Jazz Pharmaceuticals for $7.2 billion; Dyax on its sale to Shire for $6.6 billion; Tesaro on its sale to GSK for $5.1 billion; Avanir on its sale to Otsuka for $3.5 billion; Peloton Therapeutics on its sale to Merck for up to $2.2 billion; Constellation Pharmaceuticals on its sale to MorphoSys for $1.7 billion; ARMO on its sale to Eli Lilly for $1.6 billion; Relypsa on its sale to Galenica for $1.5 billion; Cadence on its sale to Mallinckrodt for $1.3 billion; Syntimmune on its sale to Alexion for up to $1.2 billion; Eidos Therapeutics on its $1.1 billion sale of its publicly traded minority shares to BridgeBio; MAP Pharmaceuticals on its sale to Allergan for $1 billion; Optimer and Trius on their sales to Cubist for $800 million and $800 million, respectively; Raptor on its sale to Horizon for $800 million; XenoPort on its sale to Arbor for $500 million; and Pionyr Immunotherapeutics on its option transaction with Gilead.

Mr. Lee holds an M.B.A. from Cornell University and a B.S. in Microbiology and Molecular Genetics from the University of California, Los Angeles.